Recent Security Class Actions

Aquestive Therapeutics Inc. Common Stock (NASDAQ: AQST)

Company Name:Aquestive Therapeutics Inc. Common Stock
Stock Symbol:NASDAQ: AQST
Class Period Start:06/16/2025
Class Period End (inclusive):01/08/2026
Filing Deadline:05/04/2026

The complaint alleges Defendants provided investors with material information pertaining to the timeline for approval and launch for Aquestive’s New Drug Application (NDA) for Anaphylm (Dibutepinephrine) sublingual film. Defendants’ statements included, among other things, confidence in the Company’s NDA submission and optimistic claims that Anaphylm would be approved by the Prescription Drug User Fee Act (PDUFA) date, January 31, 2026.